Obesity-drug developer BioAge Labs Inc. held on to a slim gain at the closing bell and natural-gas producer BKV Corp. ended flat Thursday, the day the two initial public offerings debuted.

A well-known collaborator with Eli Lilly – BioAge Labs is focusing on developing an anti-obesity drug for the elderly "by targeting the biology of human ageing", the biopharmaceutical start-up said.

Earlier this week, BioAge said in a filing it was looking to offer 10.5M shares priced between $17 and $19 per share.The ...

BioAge Labs just went public, providing it with sufficient capital for now. Its strategy is to develop a drug that enhances leading weight loss therapies. Its lead candidate may have some ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

Kristen Fortney, cofounder and CEO of BioAge Labs. BioAge's main oral, small-molecule drug candidate, azelaprag, has been tested in 265 people across eight Phase I clinical trials. In preclinical ...

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based on several promising developments at BioAge Labs, Inc ...

Kristen Fortney, cofounder and CEO of BioAge Labs. From the San Francisco Business Times. BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting ...